Theravance Biopharma, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Theravance Biopharma, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $20.00K.
- Theravance Biopharma, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was $133.00K, a 23.56% decline year-over-year.
- Theravance Biopharma, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $0.00.
- Theravance Biopharma, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $375.00K, a 15.92% decline year-over-year.
- Theravance Biopharma, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $20.00K, a 96.06% decline from fiscal 2024.
- Theravance Biopharma, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $508.00K, a 17.93% decline from fiscal 2023.
- Theravance Biopharma, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $619.00K, a 22.82% decline from fiscal 2022.
- Theravance Biopharma, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $802.00K, a 76.86% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-12-31 | $20.00K 10-K · filed 2026-03-23 | |
| 2025-03-31 | $20.00K 10-Q · filed 2025-05-12 | $528.00K derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-12-31 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $508.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2024-06-30 | $375.00K 10-Q · filed 2025-08-13 | |
| 2023-12-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $619.00K 10-K · filed 2025-03-07 |
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2023-06-30 | $446.00K 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $802.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | $1.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $487.00K 10-Q · filed 2023-08-09 | |
| 2021-12-31 | $604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.47M 10-K · filed 2023-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | |
| 2021-06-30 | $2.86M 10-Q · filed 2022-08-08 | |
| 2020-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.70M 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | |
| 2020-06-30 | $2.54M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $869.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.47M 10-K · filed 2022-02-28 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | |
| 2019-06-30 | $2.60M 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $4.17M 10-K · filed 2021-02-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | |
| 2018-06-30 | $2.74M 10-Q · filed 2019-08-05 | |
| 2017-12-31 | $3.98M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $3.17M 10-K · filed 2019-02-28 | |
| 2015-12-31 | $3.12M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |